ICC/IF image rabbit anti Vimentin polyclonal antibody 5866

rabbit anti-Vimentin polyclonal antibody 5866

$100.00 – $2,600.00

Antibody summary

Rabbit polyclonal to Vimentin
Suitable for: WB, ICC/IF, IHC
Reacts with: human, mouse, rat
Isotype: IgG
100 µL, 25 µL, 1 mL

SKU: 5866parent Categories: antibody, cell marker Tag: vimentin

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	rabbit
isotype	IgG
clonality	polyclonal
concentration	serum
applications	ICC/IF, IHC, WB
reactivity	human, mouse, rat
available sizes	1 mL, 100 µL, 25 µL

rabbit anti-Vimentin polyclonal antibody 5866

antibody
Database link: human P08670 mouse P20152 rat P31000
Tested applications WB,IHC,IHC,ICC/IF
Recommended dilutions Western blot: 1:10000 IF/ICC and IHC: 1:5000
Immunogen Full length human TH expressed in and purified from E. coli.
Size and concentration 25, 100, 1000µL and serum
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Storage buffer serum, 0.04% NaN₃ added
Purity serum
Clonality polyclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Vimentin, a key protein constituent of the intermediate filament cytoskeleton, plays a pivotal role in maintaining cellular integrity and structure. In research, vimentin has become a valuable biomarker due to its tissue-specific expression and involvement in various cellular processes. Immunohistochemical analysis of vimentin has been extensively utilized to identify and characterize mesenchymal cells, such as fibroblasts, endothelial cells, and immune cells, aiding in the study of tissue development, wound healing, and cancer progression. Additionally, vimentin has been linked to epithelial-mesenchymal transition (EMT), a critical process implicated in embryonic development and metastasis. Furthermore, efforts to develop vimentin-targeting therapies for cancer treatment have shown promise, as vimentin's involvement in EMT and tumor progression make it a potential therapeutic target for limiting cancer metastasis. Click for more on: cell markers and Vimentin
Protein names Vimentin
Gene names VIM,VIM
Protein family Intermediate filament family
Mass 53652Da
Function Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. ; Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.
Subellular location Cytoplasm Cytoplasm, cytoskeleton Nucleus matrix Cell membrane
Tissues Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.
Structure Homomer assembled from elementary dimers (PubMed:20176112). Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with BCAS3 (PubMed:17505058). Interacts with LGSN (By similarity). Interacts with SYNM (By similarity). Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with PLEC isoform 1C (PubMed:24940650). Interacts with STK33 (PubMed:18811945). Interacts with LARP6 (PubMed:21746880). Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton (PubMed:16361107, PubMed:18827015). Interacts with TOR1AIP1 (PubMed:16361107). Interacts with DIAPH1 (PubMed:23325789). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament (PubMed:16923132). Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM (PubMed:29496907). Interacts with NOD2 (PubMed:27812135). Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2) (PubMed:26845719). Interacts with PRKCE (via phorbol-ester/DAG-type 2 domain) (PubMed:18408015). Interacts with BFSP2 (By similarity). Interacts with PPL (By similarity). Interacts (via rod domain) with PKP1 (PubMed:10852826). Interacts with PKP2 (PubMed:10852826). ; (Microbial infection) Interacts with HCV core protein.
Post-translational modification Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm (PubMed:21465480). Phosphorylated by STK33 (PubMed:18811945). Phosphorylated on tyrosine residues by SRMS (PubMed:29496907). ; O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. ; S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.
Involvement in disease Cataract 30, multiple types (CTRCT30) [MIM:116300]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Note=The disease is caused by variants affecting the gene represented in this entry.
Target Relevance information above includes information from UniProt accession: P08670
The UniProt Consortium

Immunofluorescence analysis of HeLa cells costained with rabbit pAb to vimentin, 5866, dilution 1:5,000, in green, and mouse mAb to Actin, 7047, dilution 1:500, in red. Blue is DAPI staining of nuclear DNA. The vimentin antibody stains the 10nm or intermediate filament network of the cytoskeleton. The antibody to actin labels the submembranous actin-rich cytoskeleton, stress fibers, and bundles of actin associated with cell adhesion sites.

Chromogenic immunostaining of a 4% PFA fixed paraffin embedded mouse kidney section with rabbit pAb to vimentin, 5866, dilution 1:1,000, detected with DAB (brown) using the Vector Labs ImmPRESS method and reagents with Borg buffer retrieval (Biocare Medical). Hematoxylin (blue) was used as the counterstain. In this image, the 5866 antibody specifically labels the interstitium in glomerular podocytes. This antibody performs well in testing with both 4% PFA and standard NBF fixed tissues with high pH, EDTA based retrieval.

Western blot analysis of whole cell lysates using rabbit pAb to vimentin, 5866, dilution 1:5,000, in green. [1] protein standard (red), [2] HeLa, [3] SH-SY5Y, [4] HEK293, [5] NIH-3T3 cells. Strong band corresponds to vimentin protein with apparent SDS-PAGE molecular weight of ~55kDa.

Publications

pmid	title	authors	citation
35129203	Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation.	Jiali An, Dingkun Hou, Lei Wang, Lili Wang, Yuanyuan Yang, Haitao Wang	Histol Histopathol 37:597-607
33245857	Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies.	Mirko Cortese, Ji-Young Lee, Berati Cerikan, Christopher J Neufeldt, Viola M J Oorschot, Sebastian Köhrer, Julian Hennies, Nicole L Schieber, Paolo Ronchi, Giulia Mizzon, Inés Romero-Brey, Rachel Santarella-Mellwig, Martin Schorb, Mandy Boermel, Karel Mocaer, Marianne S Beckwith, Rachel M Templin, Viktoriia Gross, Constantin Pape, Christian Tischer, Jamie Frankish, Natalie K Horvat, Vibor Laketa, Megan Stanifer, Steeve Boulant, Alessia Ruggieri, Laurent Chatel-Chaix, Yannick Schwab, Ralf Bartenschlager	Cell Host Microbe 28:853-866.e5
31248980	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice.	Angela Sacco, Annalisa Bruno, Annalisa Contursi, Melania Dovizio, Stefania Tacconelli, Emanuela Ricciotti, Paloma Guillem-Llobat, Tania Salvatore, Luigia Di Francesco, Rosa Fullone, Patrizia Ballerini, Vincenzo Arena, Sara Alberti, Guizhu Liu, Yanjun Gong, Alessandro Sgambato, Carlo Patrono, Garret A FitzGerald, Ying Yu, Paola Patrignani	J Pharmacol Exp Ther 370:416-426
30015869	miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer.	Bin Wang, Liwei Sun, Jinduo Li, Rong Jiang	Mol Med Rep 18:2753-2761
28653599	[ARTICLE WITHDRAWN] MicroRNA-539 Inhibits the Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Twist-Related Protein 1-Mediated Modulation of Melanoma-Associated Antigen A4.	Zhili Cao, Xiang Zheng, Lei Cao, Naixin Liang	Oncol Res 26:529-536

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.